Treatment of Pseudomonas aeruginosa infections with pyocines.
The interactions of a contractile, a filamentous and a small pyocine with a sensitive strain of Pseudomonas aeruginosa (no. P14) were examined in vivo. The purification procedure used yielded high-activity pyocine preparations that were not toxic to mice. The inhibitory activity of such preparations, when injected into mice by various routes, was retained for up to 24 h. However, high molecular-weight pyocines given intraperitoneally in the presence of a lethal dose of strain P14 administered by the same route did not prevent the fatal outcome of infection unless they are given before or together with the bacteria. The small pyocine had no protective effect. In burned mice infected with strain P14, topical application of a filamentous pyocine failed to improve the chances of survival. The results suggest that there is little future for pyocine therapy.
D000287:Administration, Topical; D000818:Animals; D001430:Bacteriocins / Q000627:therapeutic use*; D002056:Burns / Q000150:complications / Q000188:drug therapy; D005260:Female; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D051379:Mice; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000378:metabolism; D011709:Pyocins / Q000096:biosynthesis / Q000097:blood / Q000627:therapeutic use*
D001430:Bacteriocins; D011709:Pyocins